Multiple, disseminated cutaneous metastases of vulvar squamous cell carcinoma

2004 ◽  
Vol 14 (2) ◽  
pp. 384-387
Author(s):  
F. Ghaemmaghami ◽  
M. Modares ◽  
N. Behtash ◽  
A. Z. Moosavi

Cutaneous metastases of vulvar carcinoma are extremely rare and have been reported in six patients so far. Our patient, who is the seventh one, is a 38-year-old woman with a history of diabetes mellitus.After detecting stage III squamous cell carcinoma of the vulva, she underwent radical vulvectomy and bilateral inguinal lymphadenectomy. She received 6000 cGy external beam radiation for positive margins. Six months later, she came back with multiple advanced skin lesions. Biopsy was performed and lesions were confirmed as cutaneous metastases.For her palliation, some chemotherapy drugs were prescribed. She is on her sixth chemotherapy cycle, but these skin lesions are somewhat a preterminal event and there is no well-established treatment for this phase of disease.

2016 ◽  
Vol 30 (3) ◽  
pp. 250-256 ◽  
Author(s):  
Samantha D. Swisher ◽  
Kathryn L. Phillips ◽  
Jeremy R. Tobias ◽  
John M. Cullen ◽  
Tracy L. Gieger ◽  
...  

2019 ◽  
Author(s):  
Dario R Roque ◽  
Victoria Wang

Vaginal cancer is a rare neoplasm, accounting for only 3% of gynecologic cancers. Most cases of vaginal cancer are squamous cell carcinomas, with adenocarcinoma being the second most common histopathology. As the pathophysiology of vaginal squamous cell carcinoma is thought to be due to HPV infection, treatment strategies are largely based on the treatment of cervical cancer, with radiation therapy being the primary method of definitive treatment. The role of surgery also has been shown to improve survival outcomes but should be evaluated on an individualized basis. While there continues to be no existing randomized control trials on the treatment of vaginal cancer, recent studies have explored the benefits of combination chemoradiation for advanced stage disease. Five-year survival of vaginal cancer in Stage I or II has been shown to be as high as 80-90% with treatment, while advanced disease survival rates continue to be around 30%. This review contains 2 figures, 5 tables, and 50 references. Key words: vaginal cancer, squamous cell carcinoma, brachytherapy, external beam radiation, HPV


2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Christine Ibilibor ◽  
Jeremy Wells ◽  
Sravan Kavuri ◽  
Kelvin A. Moses

Treating testicular cancer with adjuvant radiation has been associated with a number of second malignancies affecting the genitourinary tract and retroperitoneal structures; however, there have been few reported cases of cutaneous second malignancies. We report the case of a man who developed stage IV squamous cell carcinoma (SCC) of a condyloma after orchiectomy and adjuvant radiation for testicular cancer. We also review relevant literature available to date. A 55-year-old Caucasian man presented to the hospital with a large growth at the right groin which had grown into his right thigh preventing ambulation. His past medical history was significant for right testicular cancer of unknown pathology treated with orchiectomy and adjuvant radiation twenty years ago. Punch biopsy of the lesion revealed superficially invasive squamous cell carcinoma. He underwent excision of the growth with subsequent Cisplatin, radiation boost, and Paclitaxel regimens. Despite an aggressive treatment regimen and an initial good response, the patient’s cancer progressed requiring palliative care. It is unclear whether or not therapeutic radiation in this case promoted the conversion of the patient’s condyloma to a malignant lesion. Further studies are required at this time to clarify the clinical implications of these findings.


2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14057-14057
Author(s):  
J. Ahn ◽  
B. Cho ◽  
H. Choi ◽  
H. Jeung ◽  
S. Rha ◽  
...  

14057 Background: Chemoradiation is the standard treatment for anal carcinoma. Mitomycin-C (MMC) with 5-fluorouracil (5-FU) is the widely used regimen, but MMC is not a radiation sensitizer and has significant toxicities. This study was conducted to update our experience in treating anal carcinomas with an external beam radiation and continuous infusion of 5-FU with cisplatin. Methods: Twenty-eight patients with locally advanced squamous cell carcinoma of the anus were treated between 1995 and 2005. The primary tumor and involved lymph nodes received a total of 41.4–64.8 Gy and 39.6–60.4 Gy, respectively. Chemotherapy consisted of 5-FU (1,000 mg/m2 CI, D1–5 and D36–40) and cisplatin (80 mg/m2 IVF, D2 and D37) q 4weeks for 4 courses. Results: One patients had T1 lesions, 15 had T2, 7 had T3, and 5 patients had T4 disease. Seventeen patients presented with clinically detectable lymphadenopathy. Eight patients failed to start maintenance chemotherapy due to events during chemoradiation. Of the 19 patients who started maintenance chemotherapy, 3 failed to complete all four courses due to intolerance to chemotherapy. With a median follow-up duration of 68.5 months, the actuarial 5-year OS rate was 83.2 %, the DFS rate 80.7%, and the colostomy-free survival was 91.7%. Patterns of recurrence were local relapses in 3 patients, distant metastases in 2, and both in 1, respectively. Seventeen patients (60.7%) developed moist skin reaction, which frequently caused the interruption of radiotherapy. Principal grade 3/4 hematologic toxicities were neutropenia in 10 patients (35.8%) and thrombocytopenia in 4 (14.2%). The most common late complications were lymphedema (14.3%). Conclusions: Our results demonstrate that combined modality therapy with external beam radiation, cisplatin and 5-FU yields an excellent outcome in terms of survival and sphincter preservation which is comparable to the results of MMC regimens. No significant financial relationships to disclose.


2015 ◽  
Vol 7 (2) ◽  
pp. 151-155 ◽  
Author(s):  
Joon Seok ◽  
Kui Young Park ◽  
Kapsok Li ◽  
Beom Joon Kim ◽  
Joo Hyun Shim ◽  
...  

Arsenic has been classified as a class I human carcinogen, meaning that there is sufficient evidence of carcinogenicity to humans. Arsenic, however, remains a common contaminant in a number of traditional Chinese herbal balls. A 64-year-old man presented with an erythematous erosive patch on the left palm, multiple yellowish scaly patches on the right palm and an erythematous hyperkeratotic patch with bleeding on the left foot dorsum. He also had similar skin lesions on the back and buttock. He had a past medical history of chronic exposure to arsenic through consumption of traditional Chinese herbal balls. Skin biopsy revealed Bowen's disease on the left palm and squamous cell carcinoma on left foot dorsum. We report this case to emphasize that we should investigate patient's history thoroughly, including the use of Chinese herbal balls to find out arsenicism.


2000 ◽  
Vol 110 (10) ◽  
pp. 1633-1636 ◽  
Author(s):  
David M. Kaylie ◽  
Kenneth R. Stevens ◽  
Mathew Y. Kang ◽  
James I. Cohen ◽  
Mark K. Wax ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15533-e15533
Author(s):  
Takuro Ariga ◽  
Yuzuru Niibe ◽  
Takafumi Toita ◽  
Tomoko Kazumoto ◽  
Hidehiro Eto ◽  
...  

e15533 Background: To analyze treatment outcomes of young patients (age: <40 years) with uterine cervical cancer treated with definitive (chemo) radiotherapy in Japanese institutions. Methods: The records of 118 patients (age: <40 years) with cervical cancer were reviewed retrospectively. The median age was 35 years (range: 24-39 years). Clinical FIGO stages were as follows: Stages 1b1/1b2/1b/2a/2b/3a/3b/4a/unknown in 6/9/2/6/40/2/49/3/1 patients, respectively. Median maximum tumor diameter was 5.5 cm (range: 2-9.2 cm). Forty-six patients (39%) had enlarged pelvic nodes (>10 mm in the shortest diameter). One hundred five patients had squamous cell carcinoma, and 13 patients had non-squamous cell carcinoma. Definitive radiotherapy consisted of high-dose rate intracavitary brachytherapy and whole-pelvis external beam radiation therapy. The cumulative linear quadratic equivalent dose (EQD2) was 64 Gy (range: 30-80 Gy) prescribed at point A. Concurrent chemotherapy was delivered in 95 patients (81%). Results: Within a median follow-up time of 35 months, 44 patients developed recurrence. Thirty-nine patients (33%) had pelvic recurrence only, four patients (3%) had distant metastasis only, and one patient had both pelvic and distant metastasis. The 5-year overall survival rate (OS) and local control rate (LC) of all patients were 62 % and 64 %, respectively. The 5-year OS for patients with disease stages 1b1/1b2/2a/2b/3/4a were 80%/89 %/100 %/75 %/40 %/0 %, respectively. The 5-year LC for patients with disease stages 1b1/1b2/2a/2b/3/4a were 100%/78%/50%/75%/51%/0%, respectively. Twelve patients (10%) suffered grade 3 or higher late radiation morbidity. Conclusions: Our results suggest that young patients (age: <40 years) with cervical cancer, especially in locally advanced stages (stage III and IVA), might have a worse prognosis than older patients when treated with definitive (chemo) radiotherapy.


Sign in / Sign up

Export Citation Format

Share Document